William Blair Comments on Nkarta's Q2 Earnings (NASDAQ:NKTX)

Nkarta, Inc. (NASDAQ:NKTX - Free Report) - Equities research analysts at William Blair decreased their Q2 2025 earnings per share estimates for shares of Nkarta in a note issued to investors on Thursday, May 15th. William Blair analyst S. Corwin now expects that the company will post earnings of ($0.50) per share for the quarter, down from their previous estimate of ($0.45). William Blair currently has a "Market Perform" rating on the stock. The consensus estimate for Nkarta's current full-year earnings is ($1.70) per share. William Blair also issued estimates for Nkarta's Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.51) EPS and FY2025 earnings at ($1.95) EPS.

Nkarta (NASDAQ:NKTX - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.43) EPS for the quarter, topping analysts' consensus estimates of ($0.44) by $0.01.

NKTX has been the subject of several other research reports. Stifel Nicolaus reduced their price objective on shares of Nkarta from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, March 27th. Needham & Company LLC reduced their price target on Nkarta from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Thursday, May 15th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $18.00 price target on shares of Nkarta in a research report on Thursday, March 27th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $14.67.

Nkarta Price Performance

Nkarta stock traded down $0.02 during trading hours on Monday, reaching $1.75. The stock had a trading volume of 254,607 shares, compared to its average volume of 1,064,178. The company has a market cap of $124.18 million, a price-to-earnings ratio of -0.93 and a beta of 0.81. The business's 50 day moving average price is $1.80 and its 200-day moving average price is $2.15. Nkarta has a 52 week low of $1.31 and a 52 week high of $8.23.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC increased its stake in Nkarta by 118.7% during the 1st quarter. Jane Street Group LLC now owns 134,286 shares of the company's stock valued at $247,000 after purchasing an additional 852,559 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Nkarta by 13.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 681,068 shares of the company's stock valued at $1,253,000 after acquiring an additional 80,211 shares during the period. AQR Capital Management LLC increased its position in shares of Nkarta by 300.5% in the 1st quarter. AQR Capital Management LLC now owns 672,078 shares of the company's stock valued at $1,237,000 after acquiring an additional 504,272 shares during the period. AWM Investment Company Inc. increased its position in shares of Nkarta by 150.0% in the 1st quarter. AWM Investment Company Inc. now owns 1,000,000 shares of the company's stock valued at $1,840,000 after acquiring an additional 600,000 shares during the period. Finally, Alyeska Investment Group L.P. increased its position in shares of Nkarta by 54.7% in the 1st quarter. Alyeska Investment Group L.P. now owns 2,064,956 shares of the company's stock valued at $3,800,000 after acquiring an additional 730,260 shares during the period. Institutional investors and hedge funds own 80.54% of the company's stock.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.